Australia Preclinical Cro Market Size & Outlook, 2026-2033

The preclinical cro market in Australia is expected to reach a projected revenue of US$ 171.1 million by 2033. A compound annual growth rate of 10.3% is expected of Australia preclinical cro market from 2026 to 2033.
Revenue, 2025 (US$M)
$77.5
Forecast, 2033 (US$M)
$171.1
CAGR, 2026 - 2033
10.3%
Report Coverage
Australia

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Australia preclinical cro market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Australia preclinical cro market highlights

  • The Australia preclinical cro market generated a revenue of USD 77.5 million in 2025 and is expected to reach USD 171.1 million by 2033.
  • The Australia market is expected to grow at a CAGR of 10.3% from 2026 to 2033.
  • In terms of segment, preclinical optimization, efficacy & pk/pd was the largest revenue generating development stage in 2025.
  • Early CMC / Phase I–II Supply is the most lucrative development stage segment registering the fastest growth during the forecast period.


Preclinical cro market data book summary

Market revenue in 2025USD 77.5 million
Market revenue in 2033USD 171.1 million
Growth rate10.3% (CAGR from 2026 to 2033)
Largest segmentPreclinical optimization, efficacy & pk/pd
Fastest growing segmentEarly CMC / Phase I–II Supply
Historical data2021 - 2024
Base year2025
Forecast period2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationTarget Discovery, Preclinical Optimization, Efficacy & PK/PD, IND-Enabling Safety (GLP), Bioanalysis & Analytics, Early CMC / Phase I–II Supply
Key market players worldwideEurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA


Other key industry trends

  • In terms of revenue, Australia accounted for 1.2% of the global preclinical cro market in 2025.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, China preclinical cro market is projected to lead the regional market in terms of revenue in 2033.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 759.2 million by 2033.

Preclinical optimization, efficacy & pk/pd was the largest segment with a revenue share of 37.29% in 2025. Horizon Databook has segmented the Australia preclinical cro market based on target discovery, preclinical optimization, efficacy & pk/pd, ind-enabling safety (glp), bioanalysis & analytics, early cmc / phase i–ii supply covering the revenue growth of each sub-segment from 2021 to 2033.


Australia country is highly cost competitive as compared to the U.S. for early phase clinical trials. It is 28% cheaper than the U.S. before tax incentives and 60% after tax incentives. The country has a simplified regulatory process for the approval of preclinical and clinical trials.

It operates a Clinical Trial Notification scheme, which means that the regulator delegates the trial review process to ethics committees and only needs to be notified of the outcome. This, in turn, minimizes the regulatory burden on sponsors of the clinical trial, enabling them to save time & money. The Australian government is also implementing reforms to reduce study start-up times and standardize overall clinical trial costs.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Preclinical CRO Market Companies

Name Profile # Employees HQ Website
SGA View profile 11-50 Las Condes, Region Metropolitana, Chile, South America https://sgasa.cl
Crown Bioscience View profile 251-500 Santa Clara, California, United States, North America http://www.crownbio.com
Intertek Group PLC View profile 44000 33 Cavendish Square, London, United Kingdom, W1G 0PS https://www.intertek.com
Medpace Holdings Inc View profile 5800 5375 Medpace Way, Cincinnati, OH, United States, 45227 https://www.medpace.com
Wuxi AppTec Co Ltd View profile 41116 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 https://www.wuxiapptec.com
Icon PLC View profile 41150 South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 https://www.iconplc.com
Labcorp Holdings Inc View profile 67000 358 South Main Street, Burlington, NC, United States, 27215 https://www.labcorp.com
Charles River Laboratories International Inc View profile 21400 251 Ballardvale Street, Wilmington, MA, United States, 01887 https://www.criver.com
Eurofins Scientific SE View profile 61798 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 https://www.eurofins.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com

Australia Development Stage - Preclinical Cro Market size, 2025 - 2033 (US$M)

Australia Preclinical CRO Market Outlook Share, 2025 & 2033 (US$M)

Australia Development Stage - Preclinical Cro Market size, 2025 - 2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online